FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2988372437> ?p ?o ?g. }

• W2988372437 endingPage "2898" @default.
• W2988372437 startingPage "2898" @default.
• W2988372437 abstract "Introduction: 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) remains the standard of care for baseline and end of treatment scans for aggressive non-Hodgkin lymphomas (NHLs). However, the role of interim FDG-PET remains not as well defined across aggressive NHLs, especially in the era of high-intensity chemoimmunotherapy. Interim FDG-PET (iPET) can serve as an early prognostic tool, and prior studies evaluating the utility of iPET-guided treatment strategies primarily focused on diffuse large B-cell lymphomas (DLBCL) and frontline R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Classification criteria systems assessing response also differ between studies with no clear consensus between use of Deauville criteria (DC), International Harmonization Project (IHP), and the ΔSUVmax method. Methods: This study evaluates our institutional experience with iPET during treatment with DA-EPOCH ± R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin with or without Rituximab) in aggressive NHLs. We retrospectively evaluated 70 patients at Moffitt Cancer Center who started on DA-EPOCH ± R between 1/1/2014 to 12/31/2018 for aggressive NHLs. Response on interim and end-of-treatment (EOT) scans were graded per DC, IHP, and ΔSUVmax methods, and progression free survival (PFS) probability estimates were calculated with chi-square testing and Kaplan Meier method. PFS outcomes were compared between interim negative and positive scans based on each scoring method. Outcomes were also compared between groups based on interim versus EOT positive or negative scans. Results: We identified 70 patients with aggressive NHLs who received DA-EPOCH ± R at our institute. The most common diagnoses were DLBCL (61%) followed by Burkitt's lymphoma (10%), primary mediastinal B-cell lymphoma (9%), plasmablastic lymphoma (7%), gray zone lymphoma (6%), primary cutaneous large B-cell lymphoma (1%), primary effusion lymphoma (1%), and other high-grade NHL not otherwise specified (3%). Of the 43 patients with DLBCL, 21/43 (49%) had double hit lymphoma (DHL) while 7/43 (16%) had triple hit lymphoma (THL), and 3/43 (7%) had MYC-rearranged DLBCL while 2/43 (5%) had double expressor DLBCL. Thirty nine out of 70 (56%) were female, and median age at diagnosis was 58.39 years (range 22.99 - 86.86 years). Most patients had stage IV disease (49/70, 70%), and 43/70 (61%) had more than one extranodal site while 45/70 (64%) had IPI score ≥ 3. Forty-six out of 70 (66%) received central nervous system prophylaxis, most with intrathecal chemotherapy (44/70, 63%). Fifty-five out of 70 (79%) had iPET available while 6/70 (9%) had interim computerized tomography (CT) scans. Fifty-six out of 70 (80%) had EOT PET, and 4/70 (6%) had EOT CT scans. Sustained complete remission occurred in 46/70 (66%) after frontline DA-EPOCH ± R (CR1), and 12/70 (17%) were primary refractory while 5/70 (7%) had relapse after CR1. Four of 70 (6%) died before cycle 3, and 3/70 (4%) did not have long-term follow-up due to transition of care elsewhere. Median follow-up was 15.29 months (range 0.85 - 60.09 months). There was significantly better PFS observed if iPET showed DC 1-3 compared to DC 4-5 (Χ2=5.707, p=0.0169), and PFS was better if iPET was negative by IHP criteria (Χ2=4.254, p=0.0392) or ΔSUVmax method (Χ2=6.411, p=0.0113). Comparing iPET to EOT PET, there was significantly better PFS if iPET was negative with EOT PET negative (iPET-/EOT-) compared to iPET positive with EOT negative (iPET+/EOT-), and iPET+/EOT+ and iPET-/EOT+ had worse PFS after iPET-/EOT- and iPET+/EOT- respectively. This pattern in iPET/EOT PFS probability remained consistent when comparing DC (Χ2=30.041, p<0.0001), IHP (Χ2=49.078, p<0.0001), and ΔSUVmax method (Χ2=9.126, p=0.0104). These findings fit clinical expectations with positive EOT scans indicating primary refractory disease. There was no significant difference in PFS when comparing DLBCL versus non-DLBCL (Χ2=3.461, p=0.0628) or DHL/THL versus non-DHL/THL diagnoses (Χ2=2.850, p=0.0914). Conclusion: Our findings indicate a prognostic role of iPET during treatment with DA-EPOCH ± R for aggressive NHLs. Significant differences in PFS were seen when graded by DC, IHP, and ΔSUVmax methods used in prior studies and when comparing interim versus EOT response. Larger studies are needed to confirm these findings. Disclosures Bello: Celgene: Speakers Bureau. Shah:Novartis: Honoraria; AstraZeneca: Honoraria; Spectrum/Astrotech: Honoraria; Adaptive Biotechnologies: Honoraria; Pharmacyclics: Honoraria; Jazz Pharmaceuticals: Research Funding; Incyte: Research Funding; Kite/Gilead: Honoraria; Celgene/Juno: Honoraria. Sokol:EUSA: Consultancy. Chavez:Janssen Pharmaceuticals, Inc.: Speakers Bureau; Genentech: Speakers Bureau; Kite Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees." @default.
• W2988372437 created "2019-11-22" @default.
• W2988372437 creator A5023642929 @default.
• W2988372437 creator A5025137989 @default.
• W2988372437 creator A5037214066 @default.
• W2988372437 creator A5048229965 @default.
• W2988372437 creator A5068140925 @default.
• W2988372437 creator A5071938732 @default.
• W2988372437 creator A5084789778 @default.
• W2988372437 date "2019-11-13" @default.
• W2988372437 modified "2023-09-30" @default.
• W2988372437 title "Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R" @default.
• W2988372437 doi "https://doi.org/10.1182/blood-2019-122393" @default.
• W2988372437 hasPublicationYear "2019" @default.
• W2988372437 type Work @default.
• W2988372437 sameAs 2988372437 @default.
• W2988372437 citedByCount "0" @default.
• W2988372437 crossrefType "journal-article" @default.
• W2988372437 hasAuthorship W2988372437A5023642929 @default.
• W2988372437 hasAuthorship W2988372437A5025137989 @default.
• W2988372437 hasAuthorship W2988372437A5037214066 @default.
• W2988372437 hasAuthorship W2988372437A5048229965 @default.
• W2988372437 hasAuthorship W2988372437A5068140925 @default.
• W2988372437 hasAuthorship W2988372437A5071938732 @default.
• W2988372437 hasAuthorship W2988372437A5084789778 @default.
• W2988372437 hasConcept C121332964 @default.
• W2988372437 hasConcept C126322002 @default.
• W2988372437 hasConcept C1276947 @default.
• W2988372437 hasConcept C143998085 @default.
• W2988372437 hasConcept C150846664 @default.
• W2988372437 hasConcept C166957645 @default.
• W2988372437 hasConcept C2776694085 @default.
• W2988372437 hasConcept C2776755627 @default.
• W2988372437 hasConcept C2776957806 @default.
• W2988372437 hasConcept C2778559949 @default.
• W2988372437 hasConcept C2778720950 @default.
• W2988372437 hasConcept C2779338263 @default.
• W2988372437 hasConcept C2779429289 @default.
• W2988372437 hasConcept C2780317896 @default.
• W2988372437 hasConcept C2780653079 @default.
• W2988372437 hasConcept C2781214270 @default.
• W2988372437 hasConcept C2989005 @default.
• W2988372437 hasConcept C71924100 @default.
• W2988372437 hasConcept C95457728 @default.
• W2988372437 hasConceptScore W2988372437C121332964 @default.
• W2988372437 hasConceptScore W2988372437C126322002 @default.
• W2988372437 hasConceptScore W2988372437C1276947 @default.
• W2988372437 hasConceptScore W2988372437C143998085 @default.
• W2988372437 hasConceptScore W2988372437C150846664 @default.
• W2988372437 hasConceptScore W2988372437C166957645 @default.
• W2988372437 hasConceptScore W2988372437C2776694085 @default.
• W2988372437 hasConceptScore W2988372437C2776755627 @default.
• W2988372437 hasConceptScore W2988372437C2776957806 @default.
• W2988372437 hasConceptScore W2988372437C2778559949 @default.
• W2988372437 hasConceptScore W2988372437C2778720950 @default.
• W2988372437 hasConceptScore W2988372437C2779338263 @default.
• W2988372437 hasConceptScore W2988372437C2779429289 @default.
• W2988372437 hasConceptScore W2988372437C2780317896 @default.
• W2988372437 hasConceptScore W2988372437C2780653079 @default.
• W2988372437 hasConceptScore W2988372437C2781214270 @default.
• W2988372437 hasConceptScore W2988372437C2989005 @default.
• W2988372437 hasConceptScore W2988372437C71924100 @default.
• W2988372437 hasConceptScore W2988372437C95457728 @default.
• W2988372437 hasIssue "Supplement_1" @default.
• W2988372437 hasLocation W29883724371 @default.
• W2988372437 hasOpenAccess W2988372437 @default.
• W2988372437 hasPrimaryLocation W29883724371 @default.
• W2988372437 hasRelatedWork W1989214322 @default.
• W2988372437 hasRelatedWork W2034585655 @default.
• W2988372437 hasRelatedWork W2888800187 @default.
• W2988372437 hasRelatedWork W2895858698 @default.
• W2988372437 hasRelatedWork W3169495907 @default.
• W2988372437 hasRelatedWork W3212185513 @default.
• W2988372437 hasRelatedWork W4250500771 @default.
• W2988372437 hasRelatedWork W4284698212 @default.
• W2988372437 hasRelatedWork W4312704659 @default.
• W2988372437 hasRelatedWork W434765413 @default.
• W2988372437 hasVolume "134" @default.
• W2988372437 isParatext "false" @default.
• W2988372437 isRetracted "false" @default.
• W2988372437 magId "2988372437" @default.
• W2988372437 workType "article" @default.